Clinical Trials Browser

Interventional × Triple Negative Breast Neoplasms × ASTX-660 × Clear all

NCT05082259 2026-02-10

ASTEROID

Phase 1 Recruiting

BreastGynecologic

Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms

NCT06590558 2025-07-03

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1 Withdrawn

Triple Negative Breast Neoplasms